Introduction
============

Pancreatic neuroendocrine tumors (pNETs) arise from endocrine cells of the pancreas. This tumor type represents less than 3% of primary pancreatic neoplasms [@B1]. A majority of pNETs are sporadic, and the rest can be associated with hereditary diseases including multiple endocrine neoplasia type I (MEN1), von Hippel Lindau (VHL) syndrome, neurofibromatosis (NF) type I, and tuberous sclerosis (TS). The prevalence rate of pNETs has increased gradually over the past 30 years in the United States as well as in Asian countries [@B2]-[@B4]. This increase might partially be explained by improvements in diagnosis, clinical awareness, and a uniform nomenclature of pathological grading introduced by the World Health Organization (WHO) in 2010 [@B5]. Interestingly, pNET incidence and stage distribution at initial diagnosis are distinct between Caucasian and Asian populations. Asian populations have a lower incidence of pNET and fewer patients present with metastatic disease at initial diagnosis than the Caucasian population [@B2]-[@B4].

pNETs are distinct from pancreatic exocrine carcinomas with respect to their indolent clinical behavior, specific tumor immunohistochemical profiles, hormone-secreting ability (some tumors), and promising treatment response to biological and novel targeted agents rather than to traditional chemotherapy in metastatic disease. The distinguishing clinical features between pNETs and exocrine carcinomas were recently described based on their marked difference in genetic alterations. Jiao et al. first determined by whole-exome sequencing that DAXX/ATRA, MEN1, and mTOR pathways are frequently mutated in pNETs in Caucasian patients, but such mutations are rarely seen in exocrine carcinomas [@B6]. Subsequently, Yuan et al. confirmed that DAXX/ATRX and mTOR pathways were frequently mutated in Chinese patients with pNETs [@B7]. However, the frequencies and prognostic values of these mutations differ remarkably with respect to the ethnicities of patients with pNETs. These inconsistencies in pNET-associated genetic alterations can be partially explained by disease rarity, small cohort numbers, and differences in gene sequencing methodologies.

The differences in epidemiological distribution of and genetic alterations in pNETs in Western and Eastern populations imply different pNET pathogenesis between patients of different ethnicities. Furthermore, reports on the distributions and frequencies of genetic mutations are still rare for patients with pNETs, especially from Asian populations. In this study, we developed a customized sequencing panel containing 43 genes with either a known or potential association with pNETs (Table [1](#T1){ref-type="table"}), based on a detailed literature review [@B6]-[@B27]. The selected genes were categorized into five genetic pathways: the DAXX/ATRX (*DAXX* and *ATRX*), MEN1 (*MEN1*, *ARID1A*, and *PSIP1*), mTOR (*PIK3CA*, *PTEN*, *TSC1*, *TSC2*, *AKT1*, *ATM*, and *mTOR*), angiogenesis (*VHL*, *ANGPT1*, *ANGPT2*, *HIF1A*, *NF1*, *NF2*, *TEK*, and *THBS1*), and p53 (*ASCL1*, *CCNB1*, *CCND1*, *CCND2*, *CCND3*, *CCNE1*, *CCNE2*, *CDKN1B*, *RB1*, and *TP53*) pathways; and miscellaneous genes (*ALCAM*, *BIN2*, *EIF1AX*, *FOXA2*, *GERM1*, *IGFR1*, *KIT*, *MGMT*, *NEUROD1*, *PDGFRA*, *PGF*, *RET*, and *RHEB*). Using this panel, we aimed to perform a comprehensive genomic analysis to assess mutation frequencies and determine correlations between genetic alterations and clinical outcome in Taiwanese patients with pNETs.

Materials and Methods
=====================

Forty patients with pNETs, treated at the Taipei Veteran General Hospital between 1998 and 2013, were enrolled in this study retrospectively. All patients had a definite pathological diagnosis of pNETs, and those who had mixed adeno-endocrine carcinomas were excluded. All tumor specimens were formalin-fixed and paraffin-embedded. Patient data on demographics, tumor stage, and pathological grade \[as classified according to the World Health Organization 2010 definition (Ki67 index)\] were collected. Patients were followed up with, and overall survival was analyzed. The study was approved by the local institutional review board of the Taipei Veterans General Hospital (2014-01-002A).

Constructing a target-enriched sequencing library
-------------------------------------------------

The cancerous portions of pancreatic neuroendocrine tumors were isolated by a pathologist and then the genomic DNA (gDNA) was extracted from formalin-fixed paraffin-embedded tissues by a QIAamp DNA FFPE Tissue Kit (*Qiagen* Inc., Valencia, *CA USA*). The purity and concentration of gDNA samples were first confirmed by electrophoresis, Nanodrop 2000 (Thermo Scientific, USA), and a Qubit 2.0 Fluorometer (Life Technologies, USA). Double-stranded DNA (dsDNA; 2 μg) that passed quality-control steps was sheared to fragments of approximately 300 bp with an M220 focused ultrasonicator (Covaris, USA). Size distribution of the fragmented DNA was confirmed using a Bioanalyzer 2100 (Agilent Technologies, USA), and shotgun genomic libraries were then generated using KAPA Hyper Prep kits (Kapa Biosystems, USA). These libraries were examined with the Agilent Bioanalyzer 2100. In order to comprehensively analyze the 43 genes of interest, the target gene library was enriched by a NimblGen Seqcap EZ system (Roche NimblGen, INC.) targeting their exons (Supplementary Table [1](#SM0){ref-type="supplementary-material"}) according to the manufacturer\'s protocol. Captured libraries were further amplified by performing 12 cycles of ligation-mediated PCR with HiFi HotStart ReadyMix (Kapa Biosystems), followed by purification with AMPure XP beads for MiSeq sequencing.

MiSeq high-throughput sequencing and data processing
----------------------------------------------------

After library concentration was determined by real-time quantitative PCR, libraries were denatured and sequenced on a MiSeq platform with v2 reagent for paired-end sequencing (2 × 150 bp). Instrument control, cluster generation, image capture, and base calling were processed with Real Time Analysis software 1.18.54, MiSeq Control software 2.4.1.3, and MiSeq Report software 2.4.60.8. FASTQ files generated by MiSeq Report were used for further analysis. The algorithm used for analysis was described previously [@B28]. Briefly, the FASTQ files were aligned to the human reference genome (February 2009, GRCh37/hg19) using BWA software (version 0.7.4) [@B29]. Picard tools (version 1.90) were used to perform the necessary data conversion, sorting, and indexing [@B30]. For single nucleotide polymorphisms (SNPs) and small insertion/deletions (indels), Genome Analysis Toolkit (GATK; version 2.5-2) was used for variant calling by using Base/indel-calibrator and HaplotypeCaller [@B31]. Genetic variants larger than 100 bp cannot be identified by GATK, so Pindel or Breakdancer software were used to find structural variants, such as large deletions, insertions, and duplications [@B32]. The variant calls were then annotated using ANNOVAR (2014-09-09) [@B33]. Only the allele frequency of the mutation greater than 10% was included.

To exclude germline variants, those variants with allelic frequencies \>1% in either the 1000 Genomes Project or NHLBI-ESP 6500 exome project were filtered. The definition of the pathogenic mutation was mainly based on the American College of Medical Genetics guideline [@B34]. Briefly, the frameshift insertion or deletion (indel), nonsense, and splice-site variants with \>1% allele frequencies were considered as pathogenic somatic mutations. Missense variants were evaluated by SIFT and PolyPhen2 scores [@B27], [@B28]; and only missense variants with scores \>0.95 in PolyPhen2 and \<0.05 in SIFT scores were further analyzed.

Statistical analysis
--------------------

Chi-square (χ^2^) and Fisher\'s exact tests were performed to determine significant associations between genetic variables (*PIK3CA*, *AKT*, *KRAS* mutations, and PTEN loss in pancreatic cancer tissues) and clinical characteristics. Kaplan-Meier survival curves were drawn and tested by Log-rank test to evaluate differences in disease-free survival between the variables. The effects of mutations on prognosis were analyzed by univariate and COX multivariate risk models. Significant differences were defined as *P*\< 0.05.

Results
=======

Clinical characteristics of patients and DNA sequencing on the Illumina platform
--------------------------------------------------------------------------------

Clinical characteristics of the patients are listed in Table [2](#T2){ref-type="table"}. The median age at diagnosis was 55 years of age and 58% of patients were male. Most patients (67.5%) had early-stage tumors (AJCC stage I or II). The tumors were functional in 9 out of 40 patients (22.5%). Four patients (10%) had multiple tumors within the pancreas by tissue proof at the time of NET diagnosis. The percentages of patient tumors with WHO grade I, II, and III or unknown were 77.5%, 17.5%, and 5%, respectively.

Capture enrichment and NGS
--------------------------

Two independent capture experiments and MiSeq runs were performed to complete the NGS sequencing for the 40 patients. The average output was 3745.3 million per experiment and Q30 was greater than 94.0%, with \~68.0% of reads (range, 61.4-75.0%) mapping to the target region. The average mean coverage for the targeted exons was 180.0 ± 47.1, 79.9% of the exons had a coverage of ≥ 100 reads, and 90.1% of the exons had a coverage of ≥ 75 reads.

Genetic mutations
-----------------

A total of 139 genetic mutations were identified in the 43 genes in the 40 patients. The mean and median number of mutations per patient were 3.5 and 3.0 (range, 0-16), respectively**(Figure [1](#F1){ref-type="fig"}, supplementary table [1](#SM0){ref-type="supplementary-material"} and table 2)**. The order of the most frequently mutated genes (over 10%) per person was: *ATRX* (28%), *MEN1*(28%), *ASCL1* (28%), *TP53*(20%), *mTOR* (20%), *ARID1A* (20%), *VHL* (20%), *NF1*(18%), *TSC2* (18%), *DAXX*(15%), and *ANGPT2* (13%) **(Table [3](#T3){ref-type="table"})**. Both *ATRX* and *DAXX* mutations were identified in two patients (5%). We next selected genes within the same pathway for further analysis. The mutation frequencies of the MENI-, mTOR-, DAXX/ATRX-, and angiogenesis-pathway genes per person were 48%, 48%, 38%, and 45%, respectively **(Table [4](#T4){ref-type="table"})**.

Association between genetic mutations and clinicopathological characteristics
-----------------------------------------------------------------------------

Only *ATRX* mutations were more frequently detected in WHO grade I than in grade II or III tumors (35% vs. 0%, p = 0.043) **(Table [5](#T5){ref-type="table"})**. There were no differences in the patients\' clinicopathological characteristics in terms of age, gender, tumor stage, number of tumors, tumor location within the pancreas, functional status, and WHO grade for other mutations. However, a trend toward higher *MEN1*mutation rates was found in patients with multiple tumors compared to those with single tumors (75% vs. 22%, p = 0.056). Patients with metastatic disease and T2-T4 primary tumor stage of (\>2 cm in largest diameter) had higher *TP53* mutation rates than those without metastatic disease (44% vs 13%, p = 0.059), and T1 stage of primary tumor (≤2 cm in largest diameter) (28% vs 0%, p = 0.080).

When analyzing clinicopathological characteristics by rate of mutation within the same pathway **(Table [6](#T6){ref-type="table"})**, patients with WHO grade I tumors had a higher incidence of mutations in angiogenesis-pathway genes than those with WHO grade II-III tumors (58% vs 0%, p = 0.002). Patients with multiple tumors had a higher incidence of mutations in genes in the MEN1 pathway than those with single tumors (100% vs. 42%, p = 0.042), while patients with T2-T4 stage primary tumors had a trend toward lower incidence of MEN1 pathway genes mutation than those with T1 stage (38% vs. 73%, p = 0.078).

Association between genetic mutations, survival outcome, and treatment response
-------------------------------------------------------------------------------

With a median follow-up of 5.9 (range, 0.3-18.4) years, 33 patients (82.5%) remained alive. By clinicopathological factors, patients with WHO grade I tumors (Ki67 less than 2%) had significantly better survival outcomes than those with either WHO grade II or III tumors (median survival time not reached vs. 5.3 years, p = 0.009) **(Figure [2](#F2){ref-type="fig"}a)**. We first assessed alteration status of single genes with a mutation rates over 10% in this study for survival analysis. Owing to the small number of patients and the rarity of genetic mutations and deaths, both could limit the statistical power; we did not find statistically significant associations between the patient survival and presence or absence of certain genetic alterations. When analyzing survival outcome by pathway mutation rate, patients with genes mutated in the DAXX/ATRX pathway showed a trend toward better survival outcome than patients without mutations in this pathway (log rank, p = 0.12) **(Figure [2](#F2){ref-type="fig"}b)**. Patients with mutated genes in the MEN1 pathway showed a trend toward better survival than those without mutations in this pathway (long rank, p = 0.079) **(Figure [2](#F2){ref-type="fig"}c)**. Totally, 6 patients in our cohort ever received everolimus treatment. The best tumor response was partial response in 3 patients (two of these patients had mutated gene in the mTOR pathway) and stable disease in another 3 patients (two of these three patients had mutated gene in the mTOR pathway). One patient, who had no mutated gene in the angiogenesis pathway, ever received sunitinib treatment, with a best tumor response of stable disease.

Discussion
==========

Our study of a 43-gene panel for 40 Taiwanese patients with pNETs identified 139 somatic mutations. Similar to previous reports, our study showed that the majority of the mutated genes were involved in the MEN1, mTOR, or DAXX/ATRX pathways. However, there were some differences between the genetic alterations in Caucasian and Asian patients with pNETs. First, there were fewer mutated genes per patient in Asian populations (mean number of mutated genes were 3.5 in this study and 3.6 in a Chinese cohort) compared to Western population (16 from the whole exome sequencing in a Western cohort) [@B6], [@B7]. However, when using the same 43 genes panel in our study to examine the Western cohort [@B6], only 1.1 mutated genes were identified. Second, genes involved in the mTOR and angiogenesis pathways were more frequently mutated in Asian populations. Our study indicated a discrepancy between mutation profiles of Asian and Caucasian patients with pNETs. Doctors might consider these differences in ethnicity when strategizing targeted therapy for patients with pNETs.

pNETs are characterized by their high degree of vascularization and increased expression of VEGFR2/3 within tumors [@B35]-[@B39]. Microvessel density around the tumor tissues was shown to be greater in low-grade tumors than in high-grade ones [@B40], and increased expression of angiogenesis-related genes was correlated with cell differentiation and good survival outcome in patients with pNETs [@B36]. Sunitinib (sutent, Pfizer Inc, NY, USA), a small tyrosine kinase inhibitor for angiogenesis, has demonstrated clinical efficacy in improving survival outcome in patients with well-differentiated advanced pNETs, in a phase-III trial [@B41]. Sunitinib efficacy is higher in non-white patients than in white patients, and in low-grade (Ki67 \< 5%) than in high-grade tumors. However, the relationship between specific genes involved in angiogenesis in pNETs was previously unclear. None of the mutated genes involved in angiogenesis were reported in Caucasian patients with pNETs, whereas Yuan et al. reported that 41% of Chinese patients with pNETs harbored a mutated *VHL* [@B7]. Similar to the report by Yuan et al., our study identified that 45% of the angiogenesis-pathway genes were mutated in the Taiwanese patients with pNETs. Importantly, our study showed that such mutations were frequent in patients with WHO grade I tumors, which may account for the relevant clinical benefit seen in non-white, low-grade tumor patients receiving sunitinib treatment [@B41]. The treatment response of sunitinib with regard to mutated angiogenesis pathway in patients with pNETs warrants further exploration.

The mTOR pathway is central to the control of transcription and translation, and cellular migration, metabolism, proliferation, and survival [@B42]. Activation of the mTOR pathway is one of the common tumor-related signaling abnormalities, which are detected in various tumors including NETs and those in the breast and lung [@B42]-[@B44]. Around 15% of Caucasian patients with pNETs harbored gene mutations in the mTOR pathway (including those in *PTEN*, *TSC2*, and *PIK3CA*). By sequencing mTOR pathway genes with only *PTEN* and *TSC2*, Yuan observed that 54% of Chinese patients with pNETs carried gene mutations in the mTOR pathway [@B7]. In line with Yuan\'s report, our study showed that the mTOR-pathway genes were frequently mutated in the Asian patients with pNETs. In addition to the most well-known mutated genes in the mTOR pathway, our study found that other genes including *mTOR*, *AKT1*, *TSC1*, and *ATM* were also frequently mutated in the Asian patients. Therefore, detection of mutations in the mTOR pathway by sequencing only *PTEN*, *TSC2*, and *PIK3CA* in Asian patients with pNETs is not sufficiently comprehensive.

Everolimus (Afinitor, Norvatis Pharmaceuticals, NJ, USA), an mTOR inhibitor, has recently demonstrated efficacy in a phase-III trial in patients with low- or intermediate-grade pNETs (RADIANT-3 trial) [@B45]. Everolimus is more efficacious in Japanese patients than in the overall population, with 5.2- and 2.4-fold improvements in progression-free survival, respectively, compared with that by placebo [@B46]. Similar improved progression-free survival has been noted in Asian vs. Western patients treated with everolimus for other gastrointestinal and pulmonary NETs, from another phase-III (RADIANT-4) trial [@B47] and one multi-institution observational study in Taiwan [@B48]. In patients with advanced breast cancer, everolimus efficacy was positively correlated with the PI3K/AKT/mTOR-pathway mutation status [@B49]. The relative abundance of mutations in the mTOR pathway in Asian patients with pNETs might partially explain their improved response to treatment with mTOR inhibitors [@B50]. However, the correlation of mTOR-pathway mutation status with everolimus efficacy in pNETs needs to be validated in further prospective studies.

Mutations in *DAXX* and *ATRX*, both of which encode proteins involved in chromatin remodeling, were detected in 40% of pNETs [@B6]. Initially, mutations in these genes were found to be mutually exclusive [@B6]. Our study found that 2 out of 11 patients with mutated *ATRX* also have mutations in *DAXX*. A similar finding was also reported by Yuan et al., who identified 4 out of 13 patients with mutations in both *ATRX* and *DAXX* [@B7]. Tumors with wild-type *DAXX* and *ATRX* show intact nuclear expression of these genes, whereas this nuclear localization is typically lost in tumors with mutations in *DAXX* or *ATRX*. Loss of DAXX or ATRX, which had been found only in well-, but not poorly differentiated pNETs [@B50], indicated that alterations in *DAXX*/*ATRX* genes represent unique biological pNET entities. Jiao et al. reported that mutation in *DAXX/ATRX* in pNETs were associated with prolong survival relative to those patients who lacked these mutations [@B6]. In line with report from Jiao et al., our findings also confirmed that metastatic pNETs with mutations in either *DAXX* or *ATRX* has favorable outcomes. However, Yuan et al. reported the contradiction report about the prognostic value of *DAXX/ATRX* in patients with pNETs. Furthermore, mutations in both *DAXX* and *ATRX* were previously associated with shortened survival and chromosomal instability in pNETs [@B51] and leiomyosarcomas [@B52]. Collectively, the biological role and prognostic value of *DAXX* or *ATRX* mutations in patients with pNETs are discordant and this question needs further exploration.

There are some limitations to our study. Given the study\'s retrospective nature and long recruitment period, clinical practice patterns might have changed over time. Second, our study included various tumor stages, WHO grades, and antitumor strategies, and the effectiveness of each antitumor strategy on a particular tumor stage or grade may potentially affect survival. Third, because small number of patients and deaths (7 of 40 patients, 17.5%) after the median follow-up of 5.9 years, the impact of genetic alternation on survival outcome was difficult to analyze statistically. Fourth, the discrepancy of tissue sequencing among different studies may bias the results. Jiao et al. sequenced both tumor and matched normal tissue DNA, while our study and Yuan et al. sequenced tumor DNA only [@B6], [@B7]. In addition, different genome analysis kit used between our study and Yuan et al. report [@B7] for variant calling to confirm the SNPs and small indels in Asian population may turn out different results as the ethnic variations of the known SNPs. All of these divergences may partially explain there were fewer genes mutated per patient in Asian population than in Caucasian cohort. Finally, our study showed a trend toward better survival outcome in patients with mutated genes in the MEN1 pathway or DAXX/ATRX pathway than patients without those mutations, however, the difference of survival outcomes were statistically insignificance, which mainly due to the limitation of small patient numbers. Because of the rarity of the disease and diversity of treatment strategies, a well-designed multisite prospective study is necessary to address these limitations.

In conclusion, our study showed that genetic profiles of Asian patients with pNETs were distinct from that of Caucasian patients. Asian patients with pNETs were more frequently mutated for genes of the mTOR and angiogenesis pathway. This could partially explain the improved outcome observed for targeted therapy among Asian patients with pNETs.
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Kaplan-Meier overall survival curves for patients with pNETs, stratified by the status of (a) WHO grade, (b) *ATXX*/*DAXX* mutations, and (c) MEN1-pathway gene mutations.
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###### 

List of genes chosen for sequencing

  Gene      Genomic position                         Length    Exons   Coding exons   Transcrip length   Involved pathway                                   Reference
  --------- ---------------------------------------- --------- ------- -------------- ------------------ -------------------------------------------------- --------------------------------------
  AKT1      Chromosome 14: 105,235,686-105,262,088   26,402    15      13             2,866              mTOR                                               Zitzmann K, et al. 2012^8^
  ALCAM     Chromosome 3: 105,085,753-105,295,744    2,930     16      15             4,701              mesenchymal stem cell differentiation \*           Tachezy M, et al. 2011^9^
  ANGPT1    Chromosome 14: 21,152,336-21,162,345     10,009    2       1              1,222              angiogenesis                                       Chen MH, et al. 2013^10^
  ANGPT2    Chromosome 8: 6,499,651-6,563,409        63,758    9       4              5,416              angiogenesis                                       Speisky D, et al. 2012^11^
  ARID1A    Chromosome 1: 27,022,524-27,108,595      86,071    20      20             8,577              MEN1                                               Fernandez-Cuesta L, et al. 2014^12.^
  ASCL1     Chromosome 12: 103,351,464-103,354,294   209,991   16      15             4,701              p53                                                Shida T, et al. 2008^13^
  ATM       Chromosome 11: 108,093,559-108,239,826   146,267   63      62             13,147             mTOR                                               Shin JU, et al. 2012^14^
  ATRX      Chromosome X: 76,760,356-77,041,702      281,346   35      35             11,167             DAXX/ATRX                                          Jiao Y, et al. 2011^6^
  BIN2      Chromosome 12: 51,674,822-51,717,948     43,126    13      13             2,221              phagocytosis \*                                    Sánchez-Barrena MJ, et al. 2012^15^
  CCNB1     Chromosome 5: 68,462,837-68,474,072      11,235    9       9              2,169              p53                                                Shin JU, et al. 2012^14^
  CCND1     Chromosome 11: 69,455,855-69,469,242     13,387    5       5              4,307              p53                                                Jiao Y, et al. 2011^6^
  CCND2     Chromosome 12: 4,273,772-4,305,350       31,578    5       5              6,840              p53                                                Jiao Y, et al. 2011^6^
  CCND3     Chromosome 6: 41,934,933-42,050,357      115,424   5       5              2,085              p53                                                Jiao Y, et al. 2011^6^
  CCNE1     Chromosome 19: 30,302,805-30,315,215     12,410    12      11             2,043              p53                                                Jiao Y, et al. 2011^6^
  CCNE2     Chromosome 8: 94,879,770-94,896,678      16,908    12      11             3,330              p53                                                Jiao Y, et al. 2011^6^
  DAXX      Chromosome 6: 33,286,335-33,290,791      4,456     8       7              2,613              DAXX/ATRX                                          Jiao Y, et al. 2011^6^
  EIF1AX    Chromosome X: 20,142,636-20,159,962      17,326    7       7              4,427              gene expression \*                                 Fernandez-Cuesta L et al. 2014^12.^
  FOXA2     Chromosome 20: 22,561,643-22,566,093     4,450     2       2              2,422              FOXA2 and FOXA3 transcription factor networks \*   Gupta A, et al. 2008^16^
  GREM1     Chromosome 15: 33,010,175-33,026,870     16,695    2       1              4,168              signaling by BMP \*                                Chen MH, et al. 2013^10^
  HIF1a     Chromosome 14: 62,162,258-62,214,976     52,718    15      15             3,919              angiogenesis                                       Pinato DJ, et al. 2014^17^
  IGFLR1    Chromosome 15: 99,192,200-99,507,759     315,559   21      21             11,803             mRNA splicing \*                                   Hansel DE, et al. 2004^18^
  KIT       Chromosome 4: 55,524,085-55,606,881      82,796    21      21             5,186              signaling by GPCR \*                               Han X, et al. 2013^19^
  MEN1      Chromosome 11: 64,570,986-64,578,766     7,780     10      9              3,162              MEN1                                               Jiao Y, et al. 2011^6^
  MGMT      Chromosome 10: 131,265,448-131,566,271   300,823   5       5              1,759              DNA double-strand break repair \*                  Schmitt AM, et al. 2014^20^
  mTOR      Chromosome 1: 11,166,592-11,322,564      155,972   58      57             8,677              mTOR                                               Jiao Y, et al. 2011^6^
  NEUROD1   Chromosome 2: 182,541,194-182,545,603    4,409     2       1              2,852              neural stem cell differentiation \*                Shida T, et al. 2008^13^
  NF-1      Chromosome 17: 29,421,945-29,704,695     282,750   58      58             12,425             angiogenesis                                       Jiao Y, et al. 2011^6^
  NF-2      Chromosome 22: 29,999,547-30,094,587     95,040    16      16             6,025              angiogenesis                                       Jiao Y, et al. 2011^6^
  CDKN1B    Chromosome 12: 12,870,058-12,875,305     5,247     3       2              2,657              p53                                                Guo SS, et al. 2001^21^
  PDGFRA    Chromosome 4: 55,095,264-55,164,414      69,150    23      22             6,576              signaling by GPCR \*                               Knösel T, 2012^22^
  PGF       Chromosome 14: 75,408,537-75,422,487     13,950    7       7              1,927              signaling by GPCR\*                                Speisky D, et al. 2012^11^
  PIK3CA    Chromosome 3: 178,866,311-178,957,881    91,570    21      20             9,093              mTOR                                               Jiao Y, et al. 2011^6^
  PSIP1     Chromosome 9: 15,464,064-15,511,017      46,953    16      15             3,391              MEN1                                               Fernandez-Cuesta L et al. 2014^12.^
  PTEN      Chromosome 10: 89,622,870-89,731,687     108,818   9       9              9,027              mTOR                                               Jiao Y, et al. 2011^6^
  RB1       Chromosome 13: 48,877,911-49,056,122     178,211   27      2              4,840              p53                                                Yachida S, et al. 2012^23^
  RET       Chromosome 10: 43,572,475-43,625,799     53,324    20      20             5,659              signaling by GPCR\*                                Falchetti A, et al. 2008^24^
  RHEB      Chromosome 7: 151,163,098-151,217,010    53,912    8       8              2,075              signaling by GPCR\*                                Pollizzi KN, et al. 2015^25^
  THBS1     Chromosome 15: 39,873,280-39,891,667     18,387    22      21             7,775              angiogenesis                                       Chan AO, et al. 2003^26^
  TEK       Chromosome 9: 27,109,147-27,230,173      121,026   23      23             4,760              angiogenesis                                       Detjen KM, et al. 2010^27^
  TP53      Chromosome 17: 7,565,097-7,590,856       25,760    11      10             2,579              p53                                                Yachida S, et al. 2012^23^
  TSC1      Chromosome 9: 135,766,735-135,820,008    53,273    23      21             8,604              mTOR                                               Jiao Y, et al. 2011^6^
  TSC2      Chromosome 16: 2,097,466-2,138,716       41,250    42      41             6,156              mTOR                                               Jiao Y, et al. 2011^6^
  VHL       Chromosome 3: 10,183,319-10,195,354      12,035    3       3              3,737              angiogenesis                                       Yuan F, et al. 2014^7^

\* There genes were categorized as "miscellaneous" of the involved pathway.

###### 

Patient clinical characteristics

  Variable                    Category     No (%)
  --------------------------- ------------ ------------
  Median Age, years (range)                55 (19-71)
  Gender                      male         23 (57.5)
                              female       17 (42.5)
  AJCC stage                  1            12 (30)
                              2            15 (37.5)
                              3            4 (10)
                              4            9 (22.5)
  T classification            1            7 (17.5)
                              2            22 (55)
                              3            3 (7.5)
                              4            8 (20)
  N classification            0            31 (77.5)
                              1            9 (22.5)
  M classification            0            31 (77.5)
                              1            9 (22.5)
  Functional status           yes          9 (22.5)
  Tumor number                single       36 (90)
                              multiple     4 (10)
  Pancreatic location         head         16 (40)
                              other site   24 (60)
  WHO grade                   1            31 (77.5)
                              2            7 (17.5)
  Variable                    Category     No (%)
  WHO grade                   3            2 (5)

###### 

Commonly mutated genes in pancreatic neuroendocrine tumors in Taiwanese, Chinese, and Caucasian cohorts

  --------------------------------------------------------------------------
  Study    Current study\        Chinese cohort^7^\   Caucasian cohort^6^\
           (Taiwanese cohort)\   n = 37               n = 68
           n = 40                                     
  -------- --------------------- -------------------- ----------------------
  ATRX     11 (27.5%)            13 (35.1)            12 (17.6%)

  MEN1     11 (27.5%)            13 (35.1)            30 (44.1%)

  ASCL1    11 (27.5%)            n/s                  0

  TP53     8 (20%)               5 (13.5%)            2 (2.9%)

  mTOR     8 (20%)               n/s                  0

  ARID1A   8 (20%)               n/s                  0

  VHL      8 (20%)               15 (40.5%)           0

  NF1      7 (17.5)              n/s                  0

  TSC2     7 (17.5%)             16 (43.2%)           6 (8.8%)

  DAXX     6 (15%)               11 (29.7)            17 (25%)

  ANGPT2   5 (12.5%)             n/s                  0

  PIK3CA   3 (7.5%)              n/s                  1 (1.5%)

  PTEN     3 (7.5%)              7 (18.9%)            5 (7.4%)
  --------------------------------------------------------------------------

n/s: no sequencing

###### 

Mutation frequencies in cellular pathways in pancreatic neuroendocrine tumors in Taiwanese, Chinese, and Caucasian cohorts

  --------------------------------------------------------------------------------
  Study          Current study\        Chinese cohort^7^\   Caucasian cohort^6^\
                 (Taiwanese cohort)\   n = 37               n = 68
                 n = 40                                     
  -------------- --------------------- -------------------- ----------------------
  MEN1 pathway   48%                   35%^a^               44%

  DAXX/ATRX      38%                   54%                  43%

  TP53 pathway   20%                   14%^b^               3%

  VHL pathway    45%                   41%^c^               0%

  mTOR pathway   48%                   54%^d^               15%
  --------------------------------------------------------------------------------

^a^sequencing MEN1 gene only, ^b^sequencing TP53 only, ^c^sequencing VHL gene only,

^d^sequencing PTEN and TSC2 genes only.

###### 

Associations between genetic mutations and clinicopathological characteristics in pancreatic neuroendocrine tumors

  Gene   Variable                Mutation no/total patient (%)   p value
  ------ ----------------------- ------------------------------- ---------
  ATRX   WHO grade I             11/31 (35%)                     0.043
         WHO grade II or III     0/9 (0%)                        
  MEN1   Single tumor            8/36 (22%)                      0.056
         Multiple tumors         3/4 (75%)                       
  TP53   Metastatic disease      4/9 (44%)                       0.059
         No metastatic disease   4/31 (13%)                      
  TP53   Primary tumor \>2 cm    8/29 (28%)                      0.080
         Primary tumor ≤2 cm     0/11 (0%)                       

Only variables in Chi-square (χ^2^) test or Fisher\'s exact test with p \< 0.10 are presented in the table.

###### 

Associations between pathway mutations and clinicopathological characteristics in pancreatic neuroendocrine tumors

  Pathway        Variables              Mutation no/total patient (%)   p value
  -------------- ---------------------- ------------------------------- ---------
  MEN1           Single tumor           15/36 (42%)                     0.042
                 Multiple tumors        4/4 (100%)                      
  MEN1           Primary tumor \>2 cm   11/29 (38%)                     0.078
                 Primary tumor ≤2 cm    8/11 (73%)                      
  Angiogenesis   WHO grade I            18/31 (58%)                     0.002
                 WHO grade II or III    0/9 (0%)                        

Only variables in Chi-square (χ^2^) test or Fisher\'s exact test with p \< 0.10 are presented in the table.

[^1]: \* These authors contributed equally to this work.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
